Novo Nordisk petitions the FDA to exclude liraglutide from the 503B Bulks List, citing safety risks, lack of clinical need, ...

In its Citizen Petition to the FDA, Novo Nordisk argued that there is no clinical need to allow compounding for liraglutide, ...

In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...

The FDA has approved Liraglutide Injection, the first generic version of Victoza, for the treatment of type 2 diabetes.

By comparison, the FDA-approved drug liraglutide only resulted in just under 6% weight loss after 26 weeks, the researchers ...

The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide for people with type 2 diabetes, opening the door for lower-priced ...

The move intensifies an ongoing legal battle, as Novo Nordisk joins its major competitor Eli Lilly in opposing a recent initiative by the Outsourcing Facilities Association to include liraglutide in ...

The drugs were first approved to treat type 2 diabetes – and that's what the FDA said daily injections of liraglutide could ...

FDA Approves First Generic of Once-Daily GLP-1 Injection to Lower Blood Sugar in Patients with Type 2 Diabetes ...

(HealthDay News) — The US Food and Drug Administration has approved the first generic referencing Victoza (liraglutide; Hikma ...

GLP-1 receptor agonist weight loss drugs can negatively interact with eating disorder psychopathology and treatment in ...

Liraglutide injection is now approved for adult and pediatric patients ages 10 and up, proving another option amid the GLP-1 ...